<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649073</url>
  </required_header>
  <id_info>
    <org_study_id>415-102-00001</org_study_id>
    <nct_id>NCT04649073</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter, Uncontrolled, Nonrandomized, Open-Label, Phase 1/2 Trial Investigating the Safety and Efficacy of OPC 415 in MMG49 Antigen-Positive Patients With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in&#xD;
      patients with relapsed and/or refractory Multiple Myeloma (MM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">January 2041</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase1: Dose Limiting Toxicity</measure>
    <time_frame>Day1~Day28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase2: Response rate</measure>
    <time_frame>Day1~Day366</time_frame>
    <description>The proportion of subjects who achieved partial response or better outcomes by central assessment based on IMWG Uniform Response Criteria for Multiple Myeloma will be calculated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Multiple Myeloma (MM)</condition>
  <arm_group>
    <arm_group_label>OPC-415 (up to 1×10^7cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPC-415</intervention_name>
    <description>OPC-415 (up to 1×10^7cells/kg) On 2 days</description>
    <arm_group_label>OPC-415 (up to 1×10^7cells/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged between 20 and 80 (75 for the phase 1 part) years, both inclusive, at&#xD;
             the time of consent&#xD;
&#xD;
          -  Patients with a definitive diagnosis of active multiple myeloma&#xD;
&#xD;
          -  Patients who have had 2 or more prior regimens (including all proteasome inhibitors,&#xD;
             immunomodulators, and anti-CD38 antibody)&#xD;
&#xD;
          -  Patients with relapsed and/or refractory Multiple Myeloma&#xD;
&#xD;
          -  Patients who are positive for MMG49 antigen&#xD;
&#xD;
          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS)&#xD;
             score of 0 or 1. Those with an ECOG-PS score of 2 due solely to MM bone lesions can be&#xD;
             enrolled&#xD;
&#xD;
          -  Patients who are expected to survive for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are scheduled to receive high-dose chemotherapy in combination with&#xD;
             autologous stem cell transplantation as the next treatment.&#xD;
&#xD;
          -  Patients who have other active double/multiple cancers&#xD;
&#xD;
          -  Patients on continuous and systemic (oral or intravenous) medication with&#xD;
             corticosteroids or other immunosuppressive agents&#xD;
&#xD;
          -  Patients with graft-versus-host disease that requires treatment.&#xD;
&#xD;
          -  Patients who underwent a highly invasive and extensive surgical procedure within 2&#xD;
             weeks.&#xD;
&#xD;
          -  Patients who previously underwent allogeneic stem cell transplantation or organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Patients who underwent autologous stem cell transplantation within 90 days.&#xD;
&#xD;
          -  Patients with systemic amyloidosis (except localized amyloidosis without organ&#xD;
             derangement) or plasma cell leukemia.&#xD;
&#xD;
          -  Patients with prior or current central nerve involvement in MM.&#xD;
&#xD;
          -  Patients whose best ever response to MM treatment is PD.&#xD;
&#xD;
          -  Patients who previously received gene therapy or cell therapy (except hematopoietic&#xD;
             stem cell transplantation).&#xD;
&#xD;
          -  Pregnant women, nursing mothers, or women with a positive pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junji Ikeda</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Okayama Medical Center</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Medical Center</name>
      <address>
        <city>Shibuya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>:The focus of this study is a rare disease.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

